Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

IGC Pharma (IGC) Profit After Tax (2016 - 2025)

IGC Pharma (IGC) has disclosed Profit After Tax for 16 consecutive years, with -$1.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Profit After Tax fell 6.06% to -$1.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$6.4 million, a 48.72% increase, with the full-year FY2025 number at -$7.1 million, up 45.22% from a year prior.
  • Profit After Tax was -$1.8 million for Q3 2025 at IGC Pharma, down from -$1.6 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of -$1.2 million in Q1 2025 to a low of -$6.5 million in Q1 2022.
  • A 5-year average of -$2.8 million and a median of -$2.4 million in 2021 define the central range for Profit After Tax.
  • Peak YoY movement for Profit After Tax: plummeted 162.16% in 2021, then skyrocketed 67.28% in 2024.
  • IGC Pharma's Profit After Tax stood at -$2.4 million in 2021, then grew by 5.54% to -$2.2 million in 2022, then crashed by 148.51% to -$5.6 million in 2023, then surged by 67.28% to -$1.8 million in 2024, then rose by 0.44% to -$1.8 million in 2025.
  • Per Business Quant, the three most recent readings for IGC's Profit After Tax are -$1.8 million (Q3 2025), -$1.6 million (Q2 2025), and -$1.2 million (Q1 2025).